7Lowenadler B, Lycke N. Fusion proteins with heterologous T helper epitopes. Recombinant E. coli heat-stable enterotoxin proteins [J]. Int RevImmunol, 1994, 11(2): 103-11.
8Agren LC, Ekman L, Lowenadler B, et al. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A subunit [J].J lm munol, 1997, 158(8): 3936-46.
9Agren I.C, Ekman L, Lowenadler B, et al. Adjuvanticity of the cholera toxin Al-based fusion protein, CTA1 DD, is critically dependent on the ADP-rihosyltransferase and Ig-binding activity [J]. J Immunol, 1999, 162(4): 2432-40.
10Agren L, Sverremark E, Ekman L, et al. The ADP-ribosylating CTA1-DD adjuvant enhances T-cell dependent and independent responses by direct action on B cells involving anti apoptotie Bcl 2- and germinal center promoting effects [J]. J Immunol, 2000,164(12): 6276-86.
